Table 2.

Bivariate analyses between clusters S1, S2, and S3 upon SEB stimulation and clinical and biological parameters.

	Cluster S1 (n = 16)	Cluster S2 (n = 11)	Cluster S3 (n = 12)	p value
Status				< 0.001
Healthy, n (%)	10 (62.5)	0 (0)	0 (0)
Patients, n (%)	6 (37.5)	11 (100)	12 (100)
Comorbidities*,a				0.171
No, n (%)	1 (16.7)	6 (54.5)	2 (16.7)
Yes, n (%)	5 (83.3)	5 (45.5)	10 (83.3)
Median SOFA* (day 1), [IQR]	7.5 [6.2–8]	8 [6.5–10.5]	8.5 [8–10]	0.574
Median ICU length of stay*, [IQR]	4.5 [4–5.8]	10 [7.5–24]	9 [6.5–12]	0.585
Mortality at day 28*, n (%)	0 (0)	4 (36.4)	0 (0)	0.034
Median mHLA-DR* (day 3–4) (Ab/C), [IQR]	10,938 [9456–14642]	7301 [4653–11673]	3839.5 [3444–6250]	0.007
Median TNFα secretion post-LPS stimulation (pg/mL), [IQR]	3799 [2067.2–5401.2]	282.7 [122.2–861.8]	700.8 [457.8–913.3]	< 0.001

For categorical variables Chi-squared test was used and for numerical variables, t test (parametric) or Wilcoxon (non-parametric) was used.

SOFA sequential organ failure assessment, ICU intensive care unit, HLA-DR human leukocyte antigen DR, TNFα tumour necrosis factor alpha, LPS lipopolysaccharide.

*Parameters measured exclusively for septic shock patients.

^aPresence of comorbidities was affirmative when at least one of the following comorbidity was present in the patient: chronic pulmonary disease, heart failure, myocardial infarction, ulcer, diabetes, renal failure, or malign solid tumour.